Pharmaceutical

OncBioMune Pharmaceuticals announced the final patient for the first stage of their phase 1 trial of ProscaVax for prostate cancer completed treatment per protocol.

OncBioMune Pharmaceuticals (OTCQB:OBMP) announced the final patient for the first stage of their phase 1 trial of ProscaVax for prostate cancer completed treatment per protocol.
As quoted in the press release:

In the study, ProscaVax, the Company’s novel immunotherapeutic cancer vaccine consisting of a combination of tumor-associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), is being evaluated for safety, tolerability and efficacy in PSA-progressing prostate cancer in hormone-naïve and hormone-independent patients.
The interventional, open label trial is being hosted at the University of California San Diego Moores Cancer Center and the Veterans Hospital in La Jolla, California under an investigational new drug (IND) application from the U.S. Food and Drug Administration with funding from the U.S. Navy Cancer Vaccine Program. The original study design for the trial included a second stage, which OncBioMune has previously disclosed that it will forego due to favorable interim safety results from the 1A stage to initiate two separate Phase 2 clinical trials evaluating ProscaVax in both early-stage prostate cancer at Beth Israel Deaconess Medical Center and also in late-stage prostate cancer patients in a prominent hospital network in Mexico.

Click here to read the full press release.

Source: www.marketwired.com

MARKETS

Markets
TSX18864.90-213.74
TSXV615.29-11.05
DOW30896.47-132.84
S&P 5003807.20-11.63
NASD11112.74-65.15
ASX6700.20-63.40

COMMODITIES

Commodities
Gold1807.07-11.76
Silver20.36-0.38
Copper3.70-0.08
Palladium1938.50-23.50
Platinum904.83-14.17
Oil106.05-3.73
Heating Oil3.83-0.12
Natural Gas5.66-0.84

DOWNLOAD FREE REPORTS

×